You are here: Industry Insights > Market News > J&J single-dose COVID-19 vaccine gets approval for EUA in India

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

J&J single-dose COVID-19 vaccine gets approval for EUA in India

expresspharmaAugust 09, 2021

Tag: J&J , EUA , COVID-19 , India

Favorites

“Johnson and Johnson’s single-dose COVID-19 vaccine is given approval for Emergency Use in India,” tweeted Union Health Minister, Mansukh Mandaviya last week.

J&J single-dose COVID-19 vaccine gets approval for EUA in India

The company had applied last week for the Emergency Use Authorisation (EUA) of its single-dose COVID-19 vaccine in India.

“Now India has five EUA vaccines. This will further boost nation’s collective fight against COVID-19,” the tweet further informed.

The EUA submission is based on topline efficacy and safety data from the phase-III ENSEMBLE clinical trial, which demonstrated that the company’s single-shot vaccine was 85 per cent effective in preventing the disease across all regions studied.

Previous:Pharma cos foray into digital healthcare to bolster personalised care in India: GlobalData

Next:Government increases JAK storeowners’ incentive from Rs 2.50 lakhs to up to Rs 5 lakhs

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

J&J single-dose COVID-19 vaccine gets approval for EUA in India | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

J&J single-dose COVID-19 vaccine gets approval for EUA in India

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

J&J single-dose COVID-19 vaccine gets approval for EUA in India

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may likeMore>>

You may like
More>>